MA26961A1 - Agonistes selectifs des recepteurs ep4 pour le traitement de l'osteoporose - Google Patents

Agonistes selectifs des recepteurs ep4 pour le traitement de l'osteoporose

Info

Publication number
MA26961A1
MA26961A1 MA27159A MA27159A MA26961A1 MA 26961 A1 MA26961 A1 MA 26961A1 MA 27159 A MA27159 A MA 27159A MA 27159 A MA27159 A MA 27159A MA 26961 A1 MA26961 A1 MA 26961A1
Authority
MA
Morocco
Prior art keywords
bone
loss
receptors
osteoporosis
relates
Prior art date
Application number
MA27159A
Other languages
English (en)
Inventor
Kimberly O'keefe Cameron
Bruce Allen Lefker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26961A1 publication Critical patent/MA26961A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

DEPOSANT Société dite: PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 27 Novembre 2000 60/253,275 Voir en annexe le titre de l'invention et le texte de l'abrégé Agonistes sélectifs des récepteurs EP4 pour le traitement de 1'ostéoporose L'invention concerne des agonistes de prostaglandines sélectives des récepteurs EP4, de formule (I), dans laquelle R2, X, Z et Q répondent aux définitions figurant dans le présent mémoire. La présente invention concerne également des compositions pharmaceutiques contenant ces composés. La présente invention concerne également des méthodes de traitement d'affections qui comportent une faible masse osseuse, en particulier 1'ostéoporose, la fragilité, une fracture ostéoporotique, un défaut osseux, la perte de tissu osseux idiopathique de l'enfant, une perte d'os alvéolaire, une perte d'os mandibulaire, une fracture d'un os, une ostéotomie, une perte de tissu osseux associée à la périodontite ou une incarnation prostétique, chez un mammifère, comprenant l'administration de ces composés.
MA27159A 2000-11-27 2003-05-13 Agonistes selectifs des recepteurs ep4 pour le traitement de l'osteoporose MA26961A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25327500P 2000-11-27 2000-11-27

Publications (1)

Publication Number Publication Date
MA26961A1 true MA26961A1 (fr) 2004-12-20

Family

ID=22959588

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27159A MA26961A1 (fr) 2000-11-27 2003-05-13 Agonistes selectifs des recepteurs ep4 pour le traitement de l'osteoporose

Country Status (41)

Country Link
US (3) US6552067B2 (fr)
EP (1) EP1339678B1 (fr)
JP (2) JP3984164B2 (fr)
KR (1) KR20030053063A (fr)
CN (1) CN1476429A (fr)
AR (1) AR035074A1 (fr)
AT (1) ATE374182T1 (fr)
AU (1) AU2002210848A1 (fr)
BG (1) BG107697A (fr)
BR (1) BR0115687A (fr)
CA (1) CA2429850C (fr)
CY (1) CY1106976T1 (fr)
CZ (1) CZ20031257A3 (fr)
DE (1) DE60130675T2 (fr)
DK (1) DK1339678T3 (fr)
EA (1) EA200300379A1 (fr)
EC (1) ECSP034623A (fr)
EE (1) EE200300246A (fr)
ES (1) ES2291361T3 (fr)
GT (2) GT200100238AA (fr)
HN (1) HN2001000266A (fr)
HU (1) HUP0400807A2 (fr)
IL (1) IL155368A0 (fr)
IS (1) IS6775A (fr)
MA (1) MA26961A1 (fr)
MX (1) MXPA03004623A (fr)
NO (1) NO20032360L (fr)
NZ (1) NZ525164A (fr)
OA (1) OA12533A (fr)
PA (1) PA8533901A1 (fr)
PE (1) PE20020637A1 (fr)
PL (1) PL362030A1 (fr)
PT (1) PT1339678E (fr)
SI (1) SI1339678T1 (fr)
SK (1) SK5562003A3 (fr)
SV (1) SV2003000746A (fr)
TN (1) TNSN01166A1 (fr)
TW (1) TW200424170A (fr)
UY (1) UY27038A1 (fr)
WO (1) WO2002042268A2 (fr)
ZA (1) ZA200302803B (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ525164A (en) * 2000-11-27 2005-04-29 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis
ES2254726T3 (es) * 2001-07-16 2006-06-16 F. Hoffmann-La Roche Ag Analogos de prostaglandina como agonistas receptores de ep4.
EP1408961B1 (fr) 2001-07-16 2007-07-11 F. Hoffmann-La Roche Ag Derives de pyrrolidone comme antagonistes de prostanoide
CN101921220B (zh) 2001-07-23 2013-05-22 小野药品工业株式会社 治疗与骨质损失有关的疾病的含有ep4激动剂作为活性成分的药物组合物
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
EP1481976B1 (fr) 2002-03-05 2012-11-07 Ono Pharmaceutical Co., Ltd. Composes derives de 8 azaprostaglandine et medicaments contenant ceux-ci comme principe actif
WO2003077910A1 (fr) * 2002-03-18 2003-09-25 Pfizer Products Inc. Procedes de traitement au moyen d'agonistes selectifs du recepteur ep4
AU2003209571A1 (en) * 2002-03-18 2003-09-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US20050239872A1 (en) * 2002-06-06 2005-10-27 Xavier Billot 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
EP1513523A1 (fr) * 2002-06-06 2005-03-16 Merck Frosst Canada & Co. DERIVES D IMIDAZOLIDINE-2-ONE DISUBSTITUES EN 1,5 UTILES EN TANT QU AGONISTES DU RECEPTEUR EP sb 4 /sb DANS LE TRAITEME NT DE TROUBLES OCULAIRES ET DE MALADIES OSSEUSES
CA2483555A1 (fr) * 2002-06-10 2003-12-18 Applied Research Systems Ars Holding N.V. Gamma lactames utilises en tant qu'agonistes de la prostaglandine et leur utilisation
GB0219143D0 (en) * 2002-08-16 2002-09-25 Univ Leicester Modified tailed oligonucleotides
EP1563846B1 (fr) 2002-10-10 2012-08-29 Ono Pharmaceutical Co., Ltd. Promoteurs de production de facteurs de reparation endogenes
AU2003275838A1 (en) * 2002-10-25 2004-05-13 Beunard, Jean-Luc Pyrrolidin-2-on derivatives as ep4 receptor agonists
WO2004043354A2 (fr) 2002-11-08 2004-05-27 Merck & Co., Inc. Compositions ophtalmiques pour traiter l'hypertension oculaire
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
BRPI0406717A (pt) * 2003-01-10 2005-12-20 Hoffmann La Roche Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção
WO2004065365A1 (fr) * 2003-01-21 2004-08-05 Ono Pharmaceutical Co., Ltd. Derives de 8-azaprostalangine et utilisations de ces derives en tant que medicaments
CA2513652A1 (fr) 2003-03-03 2004-09-16 Applied Research Systems Ars Holding N.V. Derives de la g-lactame utilises comme agonistes de la prostaglandine
US6734201B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
WO2005012232A2 (fr) 2003-07-18 2005-02-10 Applied Research Systems Ars Holding N.V. Derives d'hydrazides constituant des modulateurs des recepteurs de la prostaglandine
US7034051B2 (en) * 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
CN1845914A (zh) 2003-09-02 2006-10-11 默克公司 用于治疗眼压过高的眼用组合物
AU2004271978B2 (en) 2003-09-04 2009-02-05 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
AU2004272546B2 (en) 2003-09-04 2007-10-18 Merck Sharp & Dohme Corp. Ophthalmic compositions for treating ocular hypertension
WO2005027931A1 (fr) * 2003-09-19 2005-03-31 Pfizer Products Inc. Compositions pharmaceutiques et methodes de traitement consistant en des associations d'un derive de la 2-alkylidene-19-nor-vitamine d et d'un agoniste selectif de ep2 ou ep4
WO2005060946A1 (fr) * 2003-12-17 2005-07-07 Pfizer Products Inc. Polytherapie continue avec des agonistes selectifs des recepteurs ep4 de la prostaglandine et un oestrogene pour le traitement de pathologies se manifestant par une faible masse osseuse
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
CN1988903A (zh) 2004-07-20 2007-06-27 默克公司 用于治疗高眼压症的眼用组合物
WO2006043655A1 (fr) * 2004-10-22 2006-04-27 Ono Pharmaceutical Co., Ltd. Préparation thérapeutique pour inhalation
JP2008518013A (ja) * 2004-10-26 2008-05-29 アラーガン、インコーポレイテッド プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法
WO2006052630A1 (fr) * 2004-11-04 2006-05-18 Allergan, Inc. Composes therapeutiques de piperidone substituee
US7547685B2 (en) * 2004-11-08 2009-06-16 Allergan, Inc. Therapeutic substituted pyrrolidone compounds
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
KR100890490B1 (ko) * 2005-01-27 2009-03-26 아사히 가세이 파마 가부시키가이샤 헤테로 6원환 화합물 및 그의 용도
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
US7772392B2 (en) 2005-05-06 2010-08-10 Allergan, Inc. Therapeutic substituted β-lactams
BRPI0611257A2 (pt) * 2005-05-06 2010-08-24 Allergan Inc beta-lactamas substituÍdas e uso em medicina do mesmo
US7893107B2 (en) * 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
KR100598678B1 (ko) * 2006-02-15 2006-07-19 (주)아이앤씨 수직형 대형 폐기물 파쇄기
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
EP2094839B1 (fr) 2006-12-08 2020-02-05 University of Rochester Expansion de cellules souches hématopoïétiques
EP2465506A1 (fr) 2006-12-18 2012-06-20 Allergan, Inc. Procédés et compositions pour traiter des maladies gastro-intestinales
AU2008246579A1 (en) 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
DK2155733T3 (da) * 2007-05-23 2012-10-29 Allergan Inc Cykliske lactamer til behandling af glaukom eller forhøjet intraokulært tryk
US8063033B2 (en) * 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
US8404736B2 (en) * 2008-08-14 2013-03-26 Beta Pharma Canada Inc. Heterocyclic amide derivatives as EP4 receptor antagonists
WO2010116270A1 (fr) 2009-04-10 2010-10-14 Pfizer Inc. Agonistes de ep2/4
KR20120093955A (ko) 2009-10-14 2012-08-23 젬머스 파마 인코포레이티드 바이러스 감염에 대한 병용 요법 치료
RU2564414C2 (ru) * 2010-03-08 2015-09-27 Какен Фармасьютикал Ко., Лтд. Новый агонист ер4
CA2738045C (fr) 2010-05-28 2019-02-19 Simon Fraser University Composes conjugues, leurs procedes de fabrication et leurs utilisations
EP2397141A1 (fr) * 2010-06-16 2011-12-21 LEK Pharmaceuticals d.d. Procédé pour la synthèse d'acides aminés beta et leurs dérivés
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
WO2012112757A2 (fr) 2011-02-17 2012-08-23 Allergan, Inc. Compositions et procédés améliorés de remplacement de tissu mou
EP2678022A2 (fr) 2011-02-23 2014-01-01 Allergan, Inc. Compositions et procédés de remplacement de tissu mou améliorés
EP2814526B1 (fr) 2012-02-16 2016-11-02 Allergan, Inc. Compositions et procédés perfectionnés de remplacement de tissu mou
WO2013123272A1 (fr) 2012-02-16 2013-08-22 Allergan, Inc. Compositions et procédés perfectionnés de remplacement de tissu mou
EP2814527A1 (fr) 2012-02-16 2014-12-24 Allergan, Inc. Compositions et procédés perfectionnés de remplacement de tissu mou
WO2013123270A1 (fr) 2012-02-16 2013-08-22 Allergan, Inc. Compositions et procédés perfectionnés de remplacement de tissu mou
HUE031885T2 (en) * 2012-07-19 2017-08-28 Cayman Chemical Co Inc Difluoro lactam preparations for EP4-mediated osteo-related diseases and conditions
ES2733998T3 (es) 2012-10-29 2019-12-03 Cardio Incorporated Agente terapéutico específico de enfermedad pulmonar
WO2014144500A2 (fr) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Procédés de synthèse d'un analogue difluorolactam
ES2635635T3 (es) * 2013-03-15 2017-10-04 Cayman Chemical Company, Incorporated Compuestos de difluorolactama como agonistas selectivos del receptor EP4 para su uso en el tratamiento de enfermedades y afecciones mediadas por EP4
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
KR20160048054A (ko) * 2013-07-19 2016-05-03 카이맨 케미칼 컴파니 인코포레이티드 골 성장의 촉진을 위한 방법, 시스템 및 조성물
KR20160042039A (ko) 2013-08-09 2016-04-18 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
ES2721525T3 (es) 2014-06-06 2019-08-01 Allergan Inc Novedosos agonistas de EP4 como compuestos terapéuticos
US9540357B1 (en) 2014-07-31 2017-01-10 Allergan, Inc. 15-aryl prostaglandins as EP4 agonists, and methods of use thereof
US10400000B2 (en) 2015-06-12 2019-09-03 Simon Fraser University Amide-linked EP4 agonist-bisphosphonate compounds and uses thereof
AU2017225999B2 (en) * 2016-03-04 2022-08-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
CN107011377B (zh) * 2017-05-03 2019-02-26 南通书创药业科技有限公司 一种β-羰基磷酸酯的制备方法
US10988468B2 (en) * 2017-12-25 2021-04-27 Asahi Kasei Pharma Corporation Nitrogen-containing 6-membered cyclic compound
WO2020237096A1 (fr) 2019-05-21 2020-11-26 Ardelyx, Inc. Combinaison pour baisser le phosphate sérique chez un patient

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1158163A (en) 1966-06-15 1969-07-16 Berk Ltd Improvements in or relating to Polymer Compositions
ZA72645B (en) * 1971-03-05 1972-11-29 Upjohn Co Prostaglandin analogs
DE2346706A1 (de) * 1973-09-17 1975-04-03 Hoechst Ag Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
US4113873A (en) 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
NL7604330A (nl) 1975-04-28 1976-11-01 Syntex Inc Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten.
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) * 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
US4177346A (en) * 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
SE423813B (sv) * 1976-08-06 1982-06-07 Pfizer Forfarande for framstellning av 1,5-disubstituerade pyrrolidoner med terapeutiska egenskaper
US4320136A (en) 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
US4456613A (en) 1982-12-27 1984-06-26 E. I. Du Pont De Nemours And Company 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof
TW288010B (fr) 1992-03-05 1996-10-11 Pfizer
SE9302334D0 (sv) 1993-07-06 1993-07-06 Ab Astra New compounds
ZA944647B (en) 1993-07-06 1995-01-06 Astra Ab Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives
US5955481A (en) 1994-03-28 1999-09-21 Nissan Chemical Industries, Ltd. Pyridine type thiazolidines
IL113112A (en) 1994-03-28 2000-06-01 Nissan Chemical Ind Ltd Pyridine substituted thiazolidinediones and pharmaceutical compositions comprising them
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
AU6427599A (en) * 1998-10-15 2000-05-01 Merck & Co., Inc. Methods for stimulating bone formation
CA2346038A1 (fr) 1998-10-15 2000-04-20 Merck & Co., Inc. Inhibition de la resorption osseuse
PL356662A1 (en) * 1999-12-22 2004-06-28 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
PT1132086E (pt) * 2000-01-31 2006-09-29 Pfizer Prod Inc Utilizacao de agonistas selectivos para o receptor da prostaglandina (pge2) 4 (ep4) para o tratamento de falha renal aguda e cronica
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
NZ525164A (en) * 2000-11-27 2005-04-29 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
IS6775A (is) 2003-04-10
DE60130675T2 (de) 2008-01-24
WO2002042268A3 (fr) 2002-07-25
NZ525164A (en) 2005-04-29
UY27038A1 (es) 2002-07-31
PL362030A1 (en) 2004-10-18
DE60130675D1 (de) 2007-11-08
ZA200302803B (en) 2004-04-13
US20040259921A1 (en) 2004-12-23
PA8533901A1 (es) 2002-11-28
US6552067B2 (en) 2003-04-22
HN2001000266A (es) 2002-01-30
MXPA03004623A (es) 2003-09-05
AU2002210848A1 (en) 2002-06-03
SV2003000746A (es) 2003-01-13
GT200100238A (es) 2002-06-26
EA200300379A1 (ru) 2003-08-28
US6747054B2 (en) 2004-06-08
WO2002042268A2 (fr) 2002-05-30
TW200424170A (en) 2004-11-16
OA12533A (en) 2006-06-05
ES2291361T3 (es) 2008-03-01
SI1339678T1 (sl) 2007-12-31
EP1339678B1 (fr) 2007-09-26
JP2007197467A (ja) 2007-08-09
NO20032360L (no) 2003-07-23
GT200100238AA (es) 2004-05-12
CN1476429A (zh) 2004-02-18
EP1339678A2 (fr) 2003-09-03
US20020065308A1 (en) 2002-05-30
EE200300246A (et) 2003-10-15
ECSP034623A (es) 2003-07-25
ATE374182T1 (de) 2007-10-15
TNSN01166A1 (fr) 2005-11-10
CA2429850A1 (fr) 2002-05-30
CZ20031257A3 (cs) 2004-04-14
JP2004521869A (ja) 2004-07-22
PE20020637A1 (es) 2002-07-18
BR0115687A (pt) 2003-09-09
CY1106976T1 (el) 2012-09-26
DK1339678T3 (da) 2008-02-04
US7192979B2 (en) 2007-03-20
CA2429850C (fr) 2008-12-30
BG107697A (en) 2004-01-30
KR20030053063A (ko) 2003-06-27
PT1339678E (pt) 2007-11-30
HUP0400807A2 (hu) 2004-07-28
JP3984164B2 (ja) 2007-10-03
AR035074A1 (es) 2004-04-14
IL155368A0 (en) 2003-11-23
SK5562003A3 (en) 2004-08-03
US20030149086A1 (en) 2003-08-07
NO20032360D0 (no) 2003-05-26

Similar Documents

Publication Publication Date Title
ECSP034623A (es) Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis
AP2001002357A0 (en) EP4 receptor selective agonists in the treatment of osteoporosis.
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
MA27009A1 (fr) Derives de pyrazole pour le traitement d'une infection par le vih
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
BR0110420A (pt) Agonistas muscarìnicos
ATE286500T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
TNSN07022A1 (fr) Derives de pyridine
MA26873A1 (fr) Derives de purine
MA27347A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
CA2407100A1 (fr) 1-aroyle-piperidinyle benzamidines
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA30296B1 (fr) Nouvelles amines
MA27017A1 (fr) Procede pour la production d'une composition pharmaceutique a faible dose ayant une distribution et activite medicamenteuses uniformes
FR2918571B1 (fr) Compositions antibiotiques a base d'huiles essentielles prophylaxie et traitement d'infections nosocomiales
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
MA30292B1 (fr) Amines primaires comme inhibiteurs de la renine
DE60225143D1 (de) Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
DE69919349D1 (de) Piperidinyl- und n-amidinopiperidinyl-derivate
MA27852A1 (fr) Derives de 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)-2,2-diphenylacetamide utilises comme antagonistes du recepteur muscarinique
UA83870C2 (ru) Замещенные бицикло[3.1.1]гептаном производные бензимидазолона и хиназолинона как агонисты человеческих рецепторов orl1
MA30924B1 (fr) Analogues de pyrazoles
IL149544A0 (en) N-ACYLPYRROLIDIN-2-YLALKYLBENZAMIDINE DERIVATIVES AS INHIBITORS OF FACTOR Xa